Lp-PLA2 (PLAC) Activity Cardiovascular Health Test

Date Presented - July 6, 2019

Ordering Doctor

Name: Dr. Jody Smith
License #: 00515515
UPIN #: A999Z9
NPI #: 9999999999

Patient Details

Jane Smith
Patient Number: 100523
DOB: Jan 1, 1980
Gender: Female
Ph: (234) 234-2343

Specimen Details

Collected: July 1, 2019
Sent: July 1, 2019
Tested: July 5, 2019
Source: Capillary Blood

Welcome To Your Results

Dear Jane Smith,

We received your small volume blood sample, and tested it for the presence of Lp-PLA2 (PLAC) activity.

The testing platform used to produce the results described in this report has been shown to detect these biomarkers to a high level of accuracy when they are present.

When shared with your healthcare professional, we are confident this report will provide insight to inform healthcare decisions that may improve your health and quality of life.

You and your healthcare professional can trust the science behind these results, as our lab partners have completed validation studies comparing this process to established testing methods.

For any questions about this test, please visit us at www.imaware.health or connect with us via email at support@imaware.health.

In good health,
The imaware team

Medical Advisory Team

Dr. Tsimikas
Director of Vascular Medicine
at the UC San Diego Health

Dr. Davidson
Preventive Cardiology
at University of Chicago

Lp-PLA2 (PLAC) Activity Cardiovascular Health Test - Your Results Summary

Jane, you **appear to have low Lp-PLA2 (PLAC) activity levels**
based on biomarker sampling. Patient specific information is listed below.

BIOMARKER SAMPLING

A biomarker ("biological marker") refers to a category of objective signs that indicate medical state. Elevated biomarker levels in your blood can signal the presence of a disease. We tested your blood for the presence of Lp-PLA2 (PLAC) activity:

PLAC

NORMAL

PATIENT SPECIFIC INFORMATION

We included specific aspects of your history and condition as part of this test in order to confirm your likelihood.

• You indicated that you don't have a family history of cardiovascular disease

• You indicated that you normal cholesterol levels

• You indicated you do not smoke

Your overall likelihood is compared to the possible scenarios

High Risk
PLAC > 225 ng/min/mL

Lower Risk
PLAC < 225 ng/min/mL

Lower Risk

Likelihood of additional risk for Cardiovascular Disease as measured by PLAC

Your likelihood estimate is based on biomarker sampling and preconditions:

Your blood sample contained abnormal biomarker levels

You indicated a pre-condition that may increase your likelihood of having this condition

Your Next Steps

Share these results with your doctor, who can review your results and provide an action plan before you make any major lifestyle changes.

If you begin to make any doctor recommended lifestyle changes, imaware™ can help you monitor the effectiveness of your lifestyle changes and treatment.

Lp-PLA2 (PLAC) Activity Cardiovascular Health Test - Detailed Results

The following pages provide additional information that should be shared with your healthcare professional. Dried blood specimen have been validated for general health screening and abnormal or unexpected results should be confirmed by a diagnostic venous collection.

DETAILED PATIENT RESULTS TABLE

Analyte	Quantitative	Qualitative	Reportable Range	Cutoff	Target Range
Lp-PLA2 (PLAC) Activity	185.0 nmol/min/mL	Low	0.0 - 382.0 nmol/min/mL	225 nmol/min/mL	0 - 225 nmol/min/mL

PATIENT DISEASE AND SYMPTOMS STATUS

• You indicated that you don't have a family history of cardiovascular disease

• You indicated that you normal cholesterol levels

• You indicated you do not smoke

## Lp-PLA2 (PLAC) Activity Test - Detailed Scientific Validation

imaware™ tests are tested to be highly accurate and precise. The following data can be reviewed by your medical professional to better understand the validity of the imaware test.

LP-PLA2 (PLAC) ACTIVITY TEST - SCIENTIFIC VALIDATION

Accuracy

Paired serum and dried serum spot samples containing varying concentrations of PLAC were tested. PLAC concentrations observed for the dried serum samples versus serum (colorimetric method) were statistically analyzed by simple regression:

N=22		
Correlation Coefficient	0.96	
Slope	1.01	
Intercept	-12.70	

	DBS PLAC	Comparable Serum Method
Mean Lp-PLA2 (PLAC)	182.36	192.74
Standard Deviation of Range	46.42	44.16

Lp-PLA2 (PLAC) Activity Cardiovascular Health Test - Additional Information

SCIENTIFIC REFERENCES

1. Sotirios Tsimikas, Johann Willeit, Michael Knoflach, Manuel Mayr, Georg Egger, Marlene Notdurfter, Joseph L. Witztum, Christian J. Wiedermann, Qingbo Xu, Stefan Kiechl, Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study, European Heart Journal, Volume 30, Issue 1, January 2009, Pages 107–115, https://doi.org/10.1093/eurheartj/ehn502

2. De Stefano, A., Mannucci, L., Tamburi, F., Cardillo, C., Schinzari, F., Rovella, V., … Tesauro, M. (2019). Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/2058738419827154

3. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Mol Diagn. 2007;7(5):511–517. doi: 10.1586/14737159.7.5.511.

4. Bonnefont-Rousselot D. (2016). [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques]. Annales Pharmaceutiques Françaises. 2016; 74(3): 190–197. doi: 10.1016/j.pharma.2015.09.002

5. Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases. Maedica (Buchar). 2010;5(1):51–55.

6. Tellis C. C., Tselepis A. D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2009;1791(5):327–338. doi: 10.1016/j.bbalip.2009.02.015

7. Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375(9725):1536–1544. doi:10.1016/S0140-6736(10)60319-4

8. Braun LT, Davidson MH. Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep 2010; 12(1) :29–33, doi: 10.1007/s11883-009-0074-y

9. Racherla S, Arora R. Utility of Lp-PLA2 in lipid-lowering therapy. Am J Ther 2012; 19(2):115-20. doi: 10.1097/MJT.0b013e3181e70d32.

PERFORMING LABORATORY INFORMATION

- Patient Sample was performed on July 5, 2019 by MyGenetx Laboratory, LLC
- CLIA Number 44D2031868
- Lab Location: 4037 Rural Plains Cir., Suite 150, Franklin, TN 37064
- Lab Director: Jack T. Pearson, M.D. .

TEST NOTES AND LIMITATIONS

- These test results should be shared with your healthcare provider
- This test is not to diagnose any health condition - only your healthcare provider can make that determination, in light of your overall health history and the results of other testing they may decide to order
- Please consult your healthcare provider before making any dietary changes
- Dried blood specimen have been validated for general health screening and abnormal or unexpected results should be confirmed by a diagnostic venous collection.